Case Report

Long-Term Benefits of Tailored Exercise in Severe Sarcoidosis: A Case Report

Alba M. Herrera-Olivares 1, Juan M. García-Manso 2, Irene Rodríguez-Gómez 3,4, Ignacio Ara 3,4, Alejandro Lucia 1,4,5,* and Alfredo Santalla 5,6

1 Faculty of Sport Sciences, Universidad Europea de Madrid, 18670 Madrid, Spain; amheroli@gmail.com
2 Hospital San Juan de Dios, Santa Cruz de Tenerife, 38009 Canary Islands, Spain; jgarciamanso@gmail.com
3 GENUD Toledo Research Group, Universidad de Castilla-La Mancha, 45004 Toledo, Spain;
Irene.Rodriguez@uclm.es (I.R.-G.); Ignacio.ara@uclm.es (I.A.)
4 CIBER of Frailty and Healthy Aging (CIBERFES), 28029 Madrid, Spain
5 Instituto de Investigación Hospital 12 de Octubre (imas12), 28041 Madrid, Spain; asanher@upo.es
6 Faculty of Sport Sciences, Universidad Pablo de Olavide, 41013 Seville, Spain
* Correspondence: alejandro.lucia@universidadeuropea.es; Tel.: +34-6613-93101; Fax: +34-9161-68265

Received: 25 October 2020; Accepted: 12 December 2020; Published: 18 December 2020

Abstract: Background: We studied the effects of a supervised, structured exercise program in a severe sarcoidosis patient. Methods: After being clinically stable for two years, a 52-year-old woman (stage IV, American Thoracic Society) who originally had irreversible lung fibrosis, pulmonary arterial hypertension (PAH), mild mitral insufficiency, and atrial dilatation, and was candidate for lung transplant, performed a combined high-intensity interval, high load resistance, and inspiratory muscle training for 4.5 years, and was tested (cardiopulmonary exercise testing and dual X-ray absorptiometry) every six months. Results: Cardiorespiratory fitness (CRF) and maximal pulmonary ventilation increased by 44% and 60%, respectively. Ventilatory efficiency also improved (decrease in the ventilatory equivalent for oxygen by 32% and 14% at the ventilatory threshold and respiratory compensation point, respectively). She improved New York Heart Association (NYHA) class (from III to II), and cardiac alterations as well as PAH reversed so that she was not in need of lung transplantation anymore. Likewise, she suffered no more episodes of hemoptysis. Bone health was overall maintained despite the post-menopausal status and the corticoid treatment. Conclusions: A long-term combined exercise intervention safely contributed—at least partly—to improve CRF and NYHA class in a patient with severe sarcoidosis, suggesting a potential coadjuvant effect to attenuate clinical manifestations.

Keywords: cardiopulmonary exercise test; pulmonary fibrosis; high-intensity interval training; inspiratory muscle training

1. Introduction

Sarcoidosis is an autoimmune disease of unknown etiology (incidence of 2.17–519/100,000 people/year [1]), characterized by the presence of noncaseating granulomas in the affected organs [2]. The condition is more common in women than men, with a peak age of onset of 30–55 years. There is high individual variability in the clinical manifestations, and many patients are asymptomatic or will have remission of symptoms within two years [3]. Sarcoidosis can affect several organs, but it preferentially affects lymph nodes and the lung where it can cause different levels of damage ranging from asymptomatic involvement to severe manifestations, including pulmonary fibrosis [4]. Pulmonary vessels might also be affected, which increase the risk of a life-threatening complication—severe pulmonary arterial hypertension (PAH) [5].
Fatigue is the most commonly reported symptom of sarcoidosis [3], which together with dyspnea, persistent cough, and physical limitations, can impair the quality of life (QoL) of symptomatic patients and lead to anxiety, depression, and social isolation [6]. Patients commonly have low levels of physical activity (PA) [7,8] and functional capacity [7,9] and, in fact, international experts recommend the implementation of exercise for treating symptomatic patients [10]. However, there is still a lack of evidence as to which training program is best (type of exercise, intensity, frequency, or duration) for this patient population [10]. In general, physical exercise interventions in patients with sarcoidosis have combined aerobic and strength exercises (as well as breathing exercises) for a maximum duration of 13 weeks [11–15]. The typical aerobic component consists of moderate-intensity continuous training (MICT, e.g., 20–30 min of walking/cycling at ≤70% of maximal aerobic capacity). In this regard, a type of exercise training that is gaining popularity in Western societies is high-intensity interval training (HIIT), because it is thought to stimulate aerobic fitness and muscle molecular adaptations that are comparable—if not superior—to those elicited by MICT despite a lower time commitment [16]. However, no study has yet assessed the long-term effects (or “adaptations”) induced by HIIT in symptomatic patients with sarcoidosis, in part because the potential exacerbation of the feeling of fatigue with intense exertion is a concern in this population [12]. Preliminary evidence has, however, indicated that a single HIIT session does not affect fatigue differently from a single MICT session in patients with sarcoidosis, supporting the need for further research on the long-term effects of HIIT for these patients [17].

Approximately 10% of patients with sarcoidosis develop end-stage fibrotic lung disease with high indication for lung transplantation [18]. Prior to this, patients may experience long-term and progressive muscle weakness [19], also affecting the inspiratory musculature [20]. Accordingly, it would be of clinical value to provide preliminary (or “proof-of-concept”) evidence on the potential benefits of programmed exercise performed over the years in those patients with a worse prognosis. Here we present the case of a patient with systemic sarcoidosis and associated severe lung affectation who underwent a supervised combined (HIIT + high load resistance + inspiratory muscle training (IMT)) program over a period of 4.5 years.

2. Experimental Section (Case Report)

The patient is a post-menopausal woman aged 52 years at the start of the study (height 162 cm; weight, 54 kg; body mass index, 20.6 kg·m⁻²), diagnosed in 2007 with the most severe presentation of systemic sarcoidosis according to the American Thoracic Society criteria—stage IV—indicating irreversible scarring in the lungs (pulmonary fibrosis) [21], in the Pulmonary Unit of the Hospital Universitario de Gran Canaria Doctor Negrín (Canary Islands, Spain).

Beyond pulmonary involvement (which also included bilateral peribronchial and mediastinal calcified lymphadenopathy and iatrogenic pneumothorax), she had ocular, dermal, and articular symptoms (Figure 1). She has been treated with corticosteroids since diagnosis and has a history of recurrent exacerbations and hemoptysis episodes of infectious origin. In 2013, she had an episode of severe acute pulmonary thromboembolism and was diagnosed with moderate PAH, diastolic atrial dilation, and mild mitral insufficiency; she was classified as New York Heart Association (NYHA) class IV. For this reason, she was also treated with anticoagulants and was considered as a candidate for eventual lung transplantation. Two years later, despite being clinically stable and having improved her status such as to be classified as NYHA class III, the patient reported a marked limitation in physical activities. She also reported that she needed to rest every ~100 m when walking in order to recover from the associated dyspnea, with recurrent episodes of hemoptysis also triggered by exertion.

She practiced athletics from the age of 17 to 20 years and adopted an essentially sedentary lifestyle since age 23 until starting our intervention—except for two 12-week respiratory rehabilitation programs performed 4 and 3 years, respectively, before the start of our exercise training intervention.
Figure 1. Graphical Abstract. Clinical and functional evolution of the patient since diagnosis of sarcoidosis. Abbreviations: HIIT, high-intensity interval training; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension.

2.1. Assessments

All assessments were performed every 6 months (June and December) at the Exercise Physiology Laboratory at Hospital 12 de Octubre (Madrid, Spain), which she first visited in June 2015. After we studied her medical history in depth (with one of us (A.L.) being a physician with solid expertise in the implementation of exercise interventions, including in-hospital programs, for patients with numerous disease conditions such as PAH [22]), she underwent a battery of physical capacity assessments (as described below) every six months. She gave her written consent to participate in the study and to have her data published. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the aforementioned institution (approval number: 13/377).

First, we measured maximum inspiratory pressure (MIP) (RPM, Micro Medical Inc., Chatham, Kent, UK). Due to the history of recurrent hemoptysis (some during spirometry) and the fact that performing forced expiration is known to increase pulmonary capillary pressure [23], we refrained from performing spirometry or maximum expiratory pressure assessments.

Thereafter, the patient performed a cycle ergometer (Ergometrics 900, Ergoline, Barcelona, Spain) exercise test until volitional exhaustion, during which blood pressure (BP), heart rate (HR), 12-lead ECG, peripheral oxygen saturation (SpO₂) (TRUSAT 3500, General Electric Oy; Helsinki, Finland) and gas exchange data (CPX Ultima, Medical Graphics Corporation, St Paul, MN, USA) were continuously monitored. We followed a published protocol [24] with slight modifications. Thus, after a 2-min resting period on the ergometer, the patient pedaled for 2 min at a cadence of 60–65 rpm without resistance (0 watt). The workload was then increased by 1 watt every 6 s (averaging 10 watts/min) until exhaustion or until SpO₂ decreased below 90%. Other criteria for test termination were chest pain, ECG signs of ischemia, severe dyspnea disproportionate to the effort, tachyarrhythmias, or a drop in BP. The protocol also included a recovery phase, during which the patient pedaled for one minute at 10 watts and one minute without resistance, before finally resting for one minute on the ergometer.
to prevent post-exercise desaturation. Gas-exchange parameters (10-s averages) where collected for the determination of the peak value of oxygen uptake ($\text{VO}_2\text{peak}$) reached during the tests, as well as the ventilatory threshold (VT) and respiratory compensation threshold (RCP, also termed “second ventilatory threshold”). The VT corresponded to the workload at which the ventilatory equivalent for oxygen (ventilation ($\text{VE} \cdot \text{VO}_2^{-1}$) starts to increase with no concomitant increase in the ventilatory equivalent for carbon dioxide ($\text{VE} \cdot \text{VCO}_2^{-1}$) and with departure from linearity of VE. The RCP was determined as the workload at which both $\text{VE} \cdot \text{VO}_2^{-1}$ and $\text{VE} \cdot \text{VCO}_2^{-1}$ increase together with a decrease in end-tidal pressure of carbon dioxide [25].

In the first visit only, the patient performed a circuit strength training session using basic machines (chest press, leg press, lateral pull down, and abdominals), during which we monitored $\text{SpO}_2$ to analyze her $\text{SpO}_2$ response (and eventual drops of this variable) during and after each set of exercises.

After the first year of training, we incorporated body composition analysis (dual X-ray absorptiometry; Hologic Discovery QDR Series, Software Physician’s Viewer, APEX System Software Version 3.1.2. Bedford, MA, USA) to the battery of assessments. Body mass composition was calculated from a full body study scan, and a specific analysis of bone density in the spine (L1-L4) and femoral neck was performed as described [26].

### 2.2. Exercise Training Intervention

The patient underwent a combined (HIIT + high load resistance + IMT) program for a total of 4.5 years in her local fitness center under the supervision of a fitness specialist. The patient generally trained five to six days/week. This included two sessions of strength training using machines, two sessions of strength training using “functional exercises”, and two HIIT sessions. When she performed two sessions per day, this consistently included a HIIT and a functional training session, respectively.

The HIIT program is detailed in Table 1. Heart rate and $\text{SpO}_2$ (TRUSAT 3500, General Electric Oy; Helsinki, Finland), and rating of perceived exertion (RPE, on a 0 to 10 scale) were recorded in each session. During the first three years all the sessions were performed on a cycle-ergometer (S-UBx, Star Trac, USA). To prevent eventual abrupt decreases in $\text{SpO}_2$ after exertion, each session ended with a cool-down phase (6 min of pedaling at 15 watts with a cadence of 60 rpm, followed by 2 min during which resistance was gradually reduced to 0). In the last phase (1.5 years) of the program, the HIIT sessions were performed on a treadmill (S-TRc, Star Trac, CA). The transition from HIIT cycle-ergometer to HIIT treadmill sessions served two purposes: (i) to apply a more functional exercise modality with a greater transference to daily life activities; and (ii) to increase the impact load associated with exercise in order to prevent—or at least attenuate—the loss of bone mineral density that is known to be associated with both post-menopause and corticosteroid treatment [27,28].

In the last month of the follow-up, and with the goal of further motivating the patient, she completed a one-mile running race at an average speed of 6.4 km/h (range 6–7) with $\text{SpO}_2$ consistently >90%. Of note, this race speed was similar to the one corresponding to the active rest periods between intervals in the treadmill HIIT sessions (Table 1).

Strength training program is detailed in Table 2. It included the same circuit on machines (chest press, leg press, lateral pull down, and abdominal) as on the first visit and was performed twice weekly. The load was progressively increased to 4 series of 7 repetitions in the sixth month. Thereafter, chest press was replaced by a modified chest fly exercise, performed with the trunk tilted ~10° forward and with grip over the shoulder (Video S1), and the lateral pull down was changed to a behind-the-neck lateral pull down executed with the trunk tilted 10° forward (Video S2). These variations were intended to expand the rib cage against the patient’s manifest dorsal hyperkyphosis.
Table 1. High-intensity interval training program.

| Period                  | Days/Week | Exercise Mode | Total Session Duration (Min) | Average Internal Load | Average HR (Beats Min⁻¹) | Average %HRmax | Average SpO₂ (%) | Number × Duration/Recovery | RPE (0-10) | Average HR (Beats Min⁻¹) | HR (%HRmax) | Average SpO₂MIN (%) |
|-------------------------|-----------|---------------|-----------------------------|-----------------------|--------------------------|----------------|-------------------|---------------------------|------------|--------------------------|---------------|--------------------|
| July–September 2015     | 4         | Cycling       | 30                          | 50% (VT-RCP)          | 125                      | 74             | 96                | 10-15 × 8 s/2-3 min     | 9          | 130                      | 77            | 93                 |
| October–December 2015   | 3-4       | Cycling       | 40-60                       | 50% (VT-RCP)          | 132                      | 79             | 94                | 14-30 × 8 s/2-3 min     | 8          | 135                      | 80            | 93                 |
| January–March 2016      | 3-4       | Cycling       | 60                          | 50% (VT-RCP)          | 135                      | 81             | 95                | 30 × 5-10 s/1 min       | 7          | 141                      | 84            | 91                 |
| April–June 2016         | 3         | Cycling       | 60                          | 50% (VT-RCP)          | 125                      | 75             | 94                | 30 × 5 s/1 min          | 7          | 135                      | 81            | 91                 |
| October–November 2016   | 3-4       | Cycling       | 45                          | 50% (VT-RCP)          | 125                      | 75             | 95                | 23 × 10 s/2 min         | 7          | 135                      | 81            | 90                 |
| December 2016           |           |               |                             |                       |                          |                |                   |                           |            |                          |               |                    |
| January–March 2017      | 3         | Cycling       | 45-60                       | 50% (VT-RCP)          | 135                      | 81             | 94                | 23-30 × 10 s/2 min      | 8          | 145                      | 87            | 90                 |
| April 2017              | 2         | Cycling       | 60                          | 50% (VT-RCP)          | 135                      | 81             | 94                | 30 × 10 s/2 min         | 8          | 145                      | 87            | 89                 |
| May–June 2017           |           |               |                             |                       |                          |                |                   |                           |            |                          |               |                    |
| July–September 2017     | 2-3       | Cycling       | 30-60                       | 50% (VT-RCP)          | 130                      | 78             | 94                | 15-30 × 10 s/2 min      | 7          | 145                      | 87            | 90                 |
| October–November 2017   | 3-3       | Cycling       | 45-60                       | 50% (VT-RCP)          | 135                      | 81             | 94                | 23-30 × 10 s/2 min      | 7          | 145                      | 87            | 90                 |
| December 2017           |           |               |                             |                       |                          |                |                   |                           |            |                          |               |                    |
| January–March 2018      | 2         | Cycling       | 60                          | 50% (VT-RCP)          | 135                      | 82             | 94                | 30 × 10 s/2 min         | 6          | 143                      | 87            | 89                 |
| April–June 2018         | 3         | Running       | 30                          | 7 km h⁻¹              | 135                      | 82             | 90                | 12 × 15 s (15 km h⁻¹)/2.5 min | 9          | 140                      | 85            | 89                 |
| July–September 2018     | 2-3       | Running       | 40-60                       | 7 km h⁻¹              | 140                      | 85             | 92                | 16-24 × 15 s (15 km h⁻¹)/2.5 min | 9          | 155                      | 94            | 91                 |
| October–December 2018   | 2         | Running       | 40-60                       | 7 km h⁻¹              | 140                      | 85             | 94                | 16-24 × 15 s (15-18 km h⁻¹)/2.5 min | 9          | 165                      | 100           | 89                 |
| January–March 2019      |           |               |                             |                       |                          |                |                   |                           |            |                          |               |                    |
| April–June 2019         | 2         | Cycling       | 30-45                       | 50% (VT-RCP)          | 135                      | 82             | 93                | 10-23 × 8 s/2-3 min     | 5          | 145                      | 88            | 89                 |
| July–September 2019     | 2         | Running       | 45                          | 7 km h⁻¹              | 135                      | 82             | 94                | 23 × 10 s (15 km h⁻¹)/2 min * | 9          | 155                      | 95            | 85                 |
| October–December 2019   | 2         | Running       | 50-45                       | 7 km h⁻¹              | 135                      | 82             | 94                | 25-23 × 10 s (15 km h⁻¹)/2 min ** | 9          | 155                      | 95            | 85                 |

Abbreviations: HR, heart rate; HRmax, age-predicted maximum heart rate (220 minus age, in years); HRpeak, peak heart rate achieved after sprint; RPE, rating of perceived exertion in Borg scale (0–10); SpO₂, peripheral oxygen saturation; SpO₂min, minimum value of SpO₂ after a sprint; 50%VT-RCP, internal (i.e., heart rate-based) work load equidistant between the ventilatory threshold and the respiratory compensation point. Symbols: * 3kg weighted vest; ** 4 kg weighted vest.
Table 2. Resistance training program.

| Period              | Days/Week | Modified Chest Fly Machine * | Leg Press | Modified Behind the Neck Lat Pulldown ** | Planks *** | Russian Belt Squat | Clean & Jerk/Split | Days/Week | Step-Full Squat | Lunges | Squat Jumps | Burpees |
|---------------------|-----------|------------------------------|-----------|-----------------------------------------|------------|-------------------|-------------------|-----------|----------------|--------|-------------|--------|
| July–September 2015 | 2         | 3 x 5–10 kg (8–92%)          | 3 x 6–10/30 kg (6–94%) | 3 x 5–15 kg (7–88%) | 2/4 x 6   | (6–94%) |                  |           |                |        |             |        |
| October–December 2015 | 2         | 4 x 7–10 kg (8–91%)          | 4 x 7–20/40 kg (6–94%) | 4 x 7–15 kg (7–88%) | 4 x 7     | (7–92%) |                  |           |                |        |             |        |
| January–March 2016  | 2         | 4 x 8–15 kg (9–91%)          | 4 x 8–50 kg (6–95%) | 4 x 8–25 kg (8–88%) | 4 x 8     | (7–94%) |                  |           |                |        |             |        |
| April–June 2016     | 2         | 4 x 8–15 kg (9–92%)          | 4 x 8–50 kg (6–95%) | 4 x 8–25 kg (8–88%) | 4 x 8     | (7–94%) |                  |           |                |        |             |        |
| July–September 2016  | 2         | 4 x 8–15 kg (9–92%)          | 4 x 8–5 x (96) kg (7–95%) | 4 x 8–25 kg (8–88%) | 4 x 8     | (7–94%) |                  |           |                |        |             |        |
| October–December 2016 |           | Decrease in medication (corticosteroids) |          |                                        |            |                   |                  |           |                |        |             |        |
| January–March 2017  | 2         | 4 x 8–15 kg (8–92%)          | 4 x 8–9(6) kg (8–85%) | 4 x 8–25 kg (8–85%) | 4 x 8     | (7–94%) |                  |           |                |        |             |        |
| April 2017          | 2         | 4 x 8–20 kg (9–90%)          | 4 x 8–60 kg (8–94%) | 4 x 8–25 kg (8–85%) | 4 x 8     | (7–94%) |                  |           |                |        |             |        |
| May–June 2017       | 0–2       | 4 x 8–20 kg (8–90%)          | 4 x 8–60 kg (7–84%) | 4 x 8–25 kg (8–85%) | 4 x 8     | (7–95%) |                  |           |                |        |             |        |
| July–September 2017  | 0–2       | 4 x 8–20 kg (8–90%)          | 4 x 8–60 kg (7–84%) | 4 x 8–25 kg (8–85%) | 4 x 8     | (7–95%) |                  |           |                |        |             |        |
| October–December 2017 |           | Progressive withdrawal of medication |          |                                        |            |                   |                  |           |                |        |             |        |
| January–March 2018  | 2         | 4 x 8–20/35 kg (7–90%)       | 4 x 8–40/70 kg (7–94%) | 4 x 8–20 kg (7–89%) | 4 x 8     | (7–95%) |                  |           |                |        |             |        |
| April–June 2018     | 2         | 4 x 8–15 kg (8–98%)          | 4 x 8–60 kg (7–94%) | 4 x 8–20 kg (7–89%) | 4 x 8     | (7–95%) |                  |           |                |        |             |        |
| July–September 2018  | 0–2       | 2/4 x 8–20 kg (7–92%)       | 2/4 x 8–70 kg (7–92%) | 2/4 x 8–25 kg (8–88%) | 2/4 x 8   | (7–95%) |                  |           |                |        |             |        |
| October–December 2018 |     0–2   | 2 x 8–20 kg (7–92%)         | 2 x 8–70 kg (7–94%) | 2 x 8–20 kg (7–88%) | 2 x 8     | (7–95%) |                  |           |                |        |             |        |
| January–March 2019  | 1–2       | 2/3 x 8–20 kg (9–88%)       | 2/3 x 8–70 kg (9–83%) | 2/3 x 8–25 kg (8–88%) | 2/3 x 8   | (8–95%) |                  |           |                |        |             |        |
| April–June 2019     | 1         | 2/3 x 8–20 kg (9–88%)       | 2/3 x 8–70 kg (9–83%) | 2/3 x 8–25 kg (9–85%) | 2/3 x 8   | (8–93%) |                  |           |                |        |             |        |
| July–September 2019  | 1         | 4 x 8–20 kg (8–92%)         | 4 x 8–70 kg (7–94%) | 4 x 8–25 kg (9–85%) | 4 x 8     | (8–95%) |                  |           |                |        |             |        |
| October–December 2019 | 1         | 4 x 8–20 kg (9–92%)         | 4 x 8–70 kg (7–95%) | 4 x 8–25 kg (8–95%) | 4 x 8     | (8–98%) |                  |           |                |        |             |        |

Classic and functional exercises were done twice a week in different days. Data are expressed in sets x reps-kg (RPE–SpO₂%). Data are expressed sets/sets, reps/ reps or kg/kg in progressive increases during a 3-months period. Burpees: dynamic combination of stand up, squat down, plank, jump out and push up. Burpees were replaced by 30+ static planks after plantar fasciitis. RPE: rating of perceived exertion in OMNI (0–10) scale in static/machine exercises and in Borg (0–10) scale in dynamic exercises. SpO₂: Lowest oxygen saturation (%) after a set. chest press in 2015, then changed to chest fly (trunk tilted –10° forward and with grip over the shoulder) 2016–2019; "trunk tilted 5° forward, with wide grip; "abdominal floor exercises (crunch, oblique crunch, crunch clap, scissors) in 2015, then changed to plank exercises (plank, plank to push up, side plank, and raised-leg plank) 2016–2019. **
Thereafter, eccentric Russian belt squat (Video S3) and, also, clean and jerk exercises were added to the gym machine routine. From the seventh month, and on different days, a functional exercise routine (step-full squats (Video S4), lunges (Video S5), step-squat jumps (Video S6), and burpees (Video S7)) was added and performed twice weekly (Table 2). HR and SpO$_2$ were continuously monitored in all sessions, as was RPE, using the 0–10 OMNI Resistance Exercise Scale [29] at the end of each exercise. The resistance training scheme aimed to allow the patient to achieve the highest maximum training volume, combining high loads and low repetitions while keeping SpO$_2$ above 90% (or at least allowing a rapid recovery of this variable to baseline levels in case it fell below 90%). This combination was selected since high loads increase maximum force more than low loads [30], and a low number of sets and repetitions have been shown as effective in increasing strength as a combination of a high number of sets and repetitions in post-menopausal women [31].

IMT was done using a mechanical pressure threshold device (Powerbreathe Plus Low Resistance, Powerbreathe Spain-Biocorp Europa; Andoain, Spain). It started with two sessions (morning and evening) of 10 maximum inspirations at 42% of MIP, five days a week, increasing gradually to 30 inspirations per session in the sixth month. Thereafter, the number of repetitions was maintained, and the inspiratory load was progressively increased depending on the patient’s intensity perception. She was asked to gradually increase the load of the inspiratory device so that it was always difficult, but not impossible, for her to do all the inspirations. After the second year, she performed two sessions of 60 inspirations per day, increasing the inspiratory load as described.

3. Results

During the study period the patient’s functional status improved from NYHA III (at the start of the intervention, in the middle of year 2015) to II (at the conclusion of the 4.5-year intervention, end of year 2019). At the end of 2016 and throughout 2017 several breaks in training occurred due to exacerbation of the disease likely associated with the progressive reduction in corticoid dosage (since clinical severity had decreased) until the withdrawal of the drug in May 2017 and reintroduction again at the start of 2018 (due to exacerbation of symptoms) (Figure 1). In addition, during January–March 2019, the patient developed plantar fasciitis that led to the suspension of HIIT during this period. Although in some months SpO$_2$ dropped below 90% after the HIIT sprints, it consistently returned to baseline levels very quickly (within 10–15 s).

Strength training was affected by medication withdrawal in the same way as HIIT (Table 2). Plantar fasciitis forced the suspension of the dynamic exercises, and the replacement of burpees with static planks. However, machine strength training was maintained throughout the duration of injury. As for the HIIT sessions, in those cases where SpO$_2$ dropped below 90% it normalized very quickly (10–15 s).

The inspiratory load increased from 20 to 40 inspirations per day at 42% of MIP, causing a 19% increase in MIP (reaching 127 cm H$_2$O). In addition to the interruptions of IMT due to the worsening of her condition after the medication withdrawal, IMT was suspended in March 2019 due to rib pain after a fall while running on the treadmill.

The effects of training in cardiopulmonary exercise testing data are shown in Table 3. Notably, VO$_2$peak and peak pulmonary ventilation increased by 44% and 60%, respectively, from the start to the end of the study period. Table 4 summarizes total and regional bone mineral density (BMD), lean and fat mass values during the study.
### Table 3. Results of cardiopulmonary exercise testing.

| Variables                  | Pretraining | December 2015 | June 2016 | December 2016 | June 2017 | December 2017 | June 2018 | December 2018 | June 2019 | December 2019 | Change from Baseline to 4.5 Years Later (%) |
|----------------------------|-------------|---------------|-----------|---------------|-----------|---------------|-----------|---------------|-----------|---------------|--------------------------------------------|
| **VO₂peak** (mL·kg⁻¹·min⁻¹) | 20.1        | 22.4          | 30.2      | 23.6          | 24.4      | 25.2          | 28.9      | 28.3          | 26.6      | 28.9          | +44%                                       |
| **VO₂max** (mL·min⁻¹)       | 1086        | 1212          | 1631      | 1275          | 1316      | 1360          | 1560      | 1550          | 1502      | 1561          | +44%                                       |
| **PPO** (watts)              | 100         | 119           | 123       | 130           | 125       | 120           | 130       | 127           | 130       | 124           | +24%                                       |
| **HRpeak** (bpm)             | 166         | 164           | 164       | 167           | 162       | 170           | 170       | 166           | 170       | 172           | +4%                                        |
| **HR (% HRmax)**             | 99          | 98            | 98        | 100           | 98        | 102           | 103       | 100           | 104       | 105           | +6%                                        |
| **VEpeak** (L/min)           | 62          | 59            | 73        | 65            | 83        | 87            | 81        | 97            | 77        | 99            | +60%                                       |
| **SpO₂peak (%)**             | 93          | 91            | 91        | 88            | 89        | 88            | 89        | 89            | 89        | 91            | −2%                                        |
| **VT**                      | 11.7        | 14.2          | 18.7      | 11.2          | 12.8      | 15.4          | 17.9      | 11.7          | 15.6      | 15.1          | +29%                                       |
| **VO₂ (mL·kg⁻¹·min⁻¹)**      | 47          | 57            | 66        | 35            | 47        | 50            | 47        | 41            | 60        | 42            | −11%                                       |
| **PE-VO₂⁻¹**                | 38          | 31            | 28        | 31            | 27        | 29            | 25        | 28            | 28        | 26            | −32%                                       |
| **VE-VO₂⁻¹**                | 39          | 35            | 35        | 39            | 33        | 38            | 35        | 34            | 34        | 36            | −3%                                        |
| **RCP**                     | 17.4        | 18.1          | 26.6      | 19.8          | 19.3      | 21.2          | 24.1      | 22.3          | 18.3      | 23.9          | +37%                                       |
| **VO₂ (mL·kg⁻¹·min⁻¹)**      | 77          | 87            | 103       | 106           | 89        | 87            | 83        | 102           | 95        | 90            | +17%                                       |
| **PE-VO₂⁻¹**                | 42          | 42            | 35        | 36            | 35        | 35            | 36        | 32            | 32        | 36            | −14%                                       |
| **VE-VO₂⁻¹**                | 36          | 37            | 33        | 32            | 35        | 32            | 32        | 33            | 33        | 37            | +3%                                        |

Abbreviations: HR, heart rate; HRmax (age-predicted maximum heart rate, i.e., 220 minus age, in years); HRpeak, peak heart rate; PO, power output; PPO, peak power output; RCP, respiratory compensation point; SpO₂, peripheral capillary oxygen saturation; VE-VO₂⁻¹, ventilatory equivalent for oxygen. VE-VCO₂⁻¹, ventilatory equivalent for carbon dioxide. VEpeak, peak ventilation; VO₂, oxygen uptake; VO₂peak, peak oxygen uptake; VT, ventilatory threshold.
Table 4. Results of body composition.

| Variables                     | Oct. 2007 | June 2016 | December 2016 | June 2017 | December 2017 | June 2018 | December 2018 | June 2019 | December 2019 | Change from Baseline to 3.5 Years Later (%) |
|-------------------------------|-----------|-----------|----------------|-----------|---------------|-----------|---------------|-----------|----------------|--------------------------------------------|
| BMD (g cm⁻²)                  |           |           |                 |           |               |           |               |           |                |                                            |
| Whole body                    | 1.11      | 1.07      | 1.07            | 1.05      | 1.06          | 1.04      | 1.02          | 1.06      |                | -4.5                                       |
| Subtotal body                 | 0.91      | 0.89      | 0.89            | 0.87      | 0.88          | 0.86      | 0.86          | 0.89      |                | -2.2                                       |
| Pelvic                        | 1.09      | 1.06      | 1.06            | 1.06      | 1.07          | 1.01      | 1.05          | 1.10      |                | 0.9                                        |
| Arms (mean)                   | 0.67      | 0.65      | 0.65            | 0.64      | 0.65          | 0.65      | 0.64          | 0.65      |                | -3.0                                       |
| Legs (mean)                   | 1.10      | 1.09      | 1.08            | 1.06      | 1.04          | 1.06      | 1.06          | 1.06      |                | -3.6                                       |
| Lumbar (mean L₁–L₄)           | 1.24      | 0.98      | 0.97            | 0.96      | 0.94          | 0.92      | 0.92          | 0.93      | 0.96           | -2.0                                       |
| T-Score spine                 | 0.4       | -0.6      | -0.7            | -0.8      | -0.9          | -1.2      | -1.1          | -1.1      |                | -0.8                                       |
| Z-Score spine                 | 1.1       | 0.4       | 0.3             | 0.3       | -0.1          | 0.0       | 0.1           | 0.1       |                | 0.4                                        |
| Femoral neck                  | 1.01      | 0.83      | 0.81            | 0.84      | 0.76          | 0.73      | 0.74          | 0.73      |                | -12.0                                      |
| T-Score femoral neck          | 0.2       | -0.1      | -0.8            | -0.3      | -0.1          | -0.8      | -1.2          | -1.0      |                | -1.1                                       |
| Z-Score femoral neck          | 0.7       | 0.8       | 0.2             | 0.7       | 1.0           | 0.2       | 0.1           | 0.1       |                | 0.1                                        |

Lean mass (kg)

| Variables       | Oct. 2007 | June 2016 | December 2016 | June 2017 | December 2017 | June 2018 | December 2018 | June 2019 | December 2019 | Change from Baseline to 3.5 Years Later (%) |
|-----------------|-----------|-----------|----------------|-----------|---------------|-----------|---------------|-----------|----------------|--------------------------------------------|
| Whole body      | 40.4      | 38.5      | 39.6            | 38.5      | 40.4          | 39.2      | 38.4          | 35.8      |                | -11.4                                      |
| Subtotal body   | 35.6      | 33.6      | 34.6            | 33.7      | 35.5          | 34.4      | 35.4          | 33.0      |                | -7.3                                       |
| Trunk           | 19.0      | 17.7      | 18.6            | 17.5      | 18.6          | 18.9      | 19.4          | 17.2      |                | -9.5                                       |
| Arms (mean)     | 2.0       | 1.9       | 2.0             | 1.9       | 2.1           | 1.9       | 1.8           | 1.9       |                | -5.0                                       |
| Legs (mean)     | 6.3       | 6.1       | 6.1             | 6.2       | 6.4           | 5.9       | 6.3           | 6.0       |                | -4.8                                       |

Fat mass (kg)

| Variables       | Oct. 2007 | June 2016 | December 2016 | June 2017 | December 2017 | June 2018 | December 2018 | June 2019 | December 2019 | Change from Baseline to 3.5 Years Later (%) |
|-----------------|-----------|-----------|----------------|-----------|---------------|-----------|---------------|-----------|----------------|--------------------------------------------|
| Whole body      | 10.3      | 12.9      | 12.9            | 12.1      | 13.9          | 14.1      | 16.3          | 15.9      |                | 54.4                                       |
| Subtotal body   | 9.6       | 12.2      | 12.1            | 11.4      | 13.2          | 13.3      | 15.6          | 15.2      |                | 58.3                                       |
| Trunk           | 3.7       | 4.9       | 4.7             | 4.6       | 5.3           | 5.4       | 6.2           | 6.3       |                | 70.3                                       |
| Arms (mean)     | 0.3       | 0.4       | 0.4             | 0.4       | 0.5           | 0.5       | 0.7           | 0.6       |                | 100                                        |
| Legs (mean)     | 2.6       | 3.2       | 3.3             | 3.0       | 3.5           | 3.4       | 4.0           | 3.9       |                | 50                                         |
| Fat mass (%)    | 20.3      | 26.0      | 24.6            | 23.9      | 25.6          | 26.4      | 28.8          | 29.7      |                | 46.3                                       |

Abbreviations: BMD, bone mineral density.
4. Discussion

The main finding of our study was that a combined (HIIT + strength + IMT) program, applied for 4.5 years in a patient with sarcoidosis (stage IV) and pulmonary involvement and treated with corticoids for 12 years, contributed—at least partly—to increase functional capacity (improving a class in the NYHA classification) as well as cardiorespiratory fitness (CRF, i.e., increase in VO$_2$peak from barely ~6 metabolic equivalents (MET) at the start of the study to 8.3 MET at the end). This is an important finding because the VO$_2$peak level reflects the synergistic action of pulmonary, cardiovascular and muscle tissue via a suite of physiological actions that effectively transport and deliver oxygen from the atmosphere to mitochondria in working muscles [32]. CRF, as determined by VO$_2$peak, is a strong prognostic factor of morbimortality, particularly in relation to cardiometabolic diseases [33]. Moreover, it is of clinical importance to surpass the eight-MET threshold, and in fact adults with a VO$_2$peak above this level have a reduced cardiovascular risk [34]. Of note, the increase in CRF was corroborated—being in fact of the same relative magnitude—when VO$_2$peak was expressed in either absolute units (mL·min$^{-1}$) or relative to body mass (mL·kg$^{-1}$·min$^{-1}$). Furthermore, the intervention was safe, with no persistent SpO$_2$ drops or syncope episodes.

A reduced maximum exercise capacity is related to frailty, conceptually defined as a physical vulnerability to stressors. Frailty is considered an important phenotype in lung transplant candidates independent of the severity of the disease [35]. On the other hand, 10% of patients with sarcoidosis progress to fibrotic lung disease and may be in need of lung transplant [18]. In this regard, although lung transplantation was originally proposed as a future option for our patient, the remission of right atrium dilatation, mild mitral insufficiency, and PAH, together with improvements in NYHA class and CRF made it possible to discard transplant by the end of first year of the intervention.

HIIT induces both peripheral (increased muscle capillary density and mitochondrial content) and central (increased cardiac output) cardiovascular adaptations [36]. Furthermore, HIIT can increase alveolar capillary density through nitric oxide-induced vascular endothelial growth factor (VEGF) [37]. In fact, the HIIT protocol used here was designed to allow the accumulation of as many training loads near VO$_2$peak as possible without drops in SpO$_2$. One the one hand, and likely related to this, we observed an improvement in ventilatory efficiency, as expressed in VE·VO$_2$·min$^{-1}$ at submaximal intensities (which decreased by 32% and 14% at VT and RCP, respectively, with the latter value similar to that of healthy subjects) [38]. Improved ventilatory efficiency might have contributed, at least in part, to the observed increase in the patient’s functional independence and the absence of high SpO$_2$ drops in her daily life activities.

IMT has been shown to improve exercise capacity, functionality, respiratory muscle strength, dyspnea, and fatigue in patients with sarcoidosis [39]. These improvements can be explained by the resulting increase in respiratory muscle strength [40] and are reflected by increases in MIP and peak ventilation during exercise. IMT-induced improvements in lung compliance can increase the surface of gas exchange [41]. Furthermore, IMT decreases the oxygen cost of breathing [41], thereby reducing the fatigue-induced respiratory metabolic reflex with subsequent increases in blood flow to locomotor muscles [42].

Resistance training may also have played a role in increasing the VO$_2$peak (mL/min) and improving the patient’s NYHA functional class. The increase in maximum strength may have allowed her, at least partly, to maintain a higher training work rate and increase the ability to cope with—and adapt to—cumulative HIIT sessions. Resistance training is known to improve work economy [43] and thus decreases the percentage of work demanded by daily life activities (e.g., walking, climbing stairs, and carrying bags); it thus allows performing these submaximal actions with less oxygen cost [44]. Muscle mass could have been affected by the patient’s menopause and prednisone treatment. Menopause frequently causes sarcopenia, which is a syndrome characterized by a progressive and generalized loss of skeletal muscle mass and strength [45]. Likewise, corticoid treatment reduces protein synthesis and increases muscle protein catabolism [46], especially in type II fibers [47]. Although muscle mass contributes to improvements in strength, our approach was actually designed to improve
muscle strength through neural factors, by increasing motor unit recruitment and firing frequency of active motor units without the need for major increases in muscle mass [48]. This is in fact why high loads were used, as they increase neural adaptations compared with lower loads [49]. In this regard, a previous study applied high-load strength training to patients with sarcoidosis for 12 weeks [13]. Although the relatively short training duration of that study suggests that the strength gains noted were likely due to neural factors, the absence of muscle mass measurements and the persistence of adaptations five months after the training period makes it difficult to quantify the neural factor influence. Our results are, however, in line with the Kullberg et al. study regarding the feasibility, safety and effectiveness of high-load resistance training in patients with sarcoidosis.

It is widely known that bone and lean mass decrease with age, particularly in menopausal women due to hormonal changes [50]. Corticoids also accelerate the loss of bone mass [51] whereas the opposite effect is seen with exercise, which is in fact recommended for the prevention of osteoporosis and osteopenia [52]. Our results would support the beneficial effect of exercise on bone health, since we observed only a slight decrease in BMD over the three-year period despite the post-menopausal status of the patient and the corticoid treatment she received for years. Indeed, analysis at the end of the follow-up revealed only mild osteopenia of the femoral neck and normal bone health at the spine (T-score = −1.1 and −0.8, respectively), indicating that our patient was above the average for women of her age (Z-score range = 0.1–0.4). Similarly, the exercise intervention probably had a certain beneficial effect on lean mass, which decreased only in the last measurement likely due to the reduction in the volume of strength training, which dropped from 4 to 2 days/week after a plantar fasciitis.

The NYHA class improvement, together with the well-known deleterious effects of chronic corticoid treatment led to the progressive withdrawal of this drug after 1.5 years from the start of the training program. With the exception of the sarcoidosis flare-up caused by medication withdrawal, only one sarcoidosis-related hospital admission (due to respiratory infection) and one medical intervention (capsulotomy) related to sarcoidosis occurred in the 4.5 years. Adverse events related to training were a running fall from the treadmill (not associated with arterial oxygen desaturation) and plantar fasciitis. Despite these episodes, the patient maintained her adherence to the training program due to the positive impact that the improvement in QoL and wellbeing early during the intervention (in the first few months) had on her level of motivation, as well as to her strong self-discipline.

The present study has several limitations that should be considered. First, as this is a case report, our preliminary results in only one patient must be interpreted with caution and cannot be generalized to all patients with sarcoidosis. In this regard, it would be interesting to conduct a randomized controlled trial with a long-term intervention like the present one, although this type of study might be very difficult to conduct. Second, the 1RM was not evaluated, and thus although an increase in load (kg) was observed with resistance training, we could not quantify the magnitude of the actual improvement in maximum strength. Finally, diet was not controlled.

5. Conclusions

In summary, the results of this study suggest that a long-term combined (HIIT + strength + IMT) exercise intervention might have contributed, at least partly, to safely improve CRF and functional capacity (NYHA class) in a patient with severe thoracic sarcoidosis. Our results also suggest that the intervention could have acted as a coadjuvant treatment that helped to partially reduce the severity of associated pathologies (cardiac involvement and PAH) and attenuate the loss of BMD and muscle mass caused by menopause and chronic corticoid treatment. Randomized controlled trials are needed to confirm our preliminary findings.

Supplementary Materials: The following are available online at http://www.mdpi.com/1660-4601/17/24/9512/s1, Video S1: Modified Chest Fly exercise, Video S2: Modified Lat Pull Down exercise, Video S3: Russian Belt Squat exercise, Video S4: Step-full squat exercise, Video S5: Lunge exercise, Video S6: Step-squat jump exercise, Video S7: Burpee exercise.
Author Contributions: Conceptualization, J.M.G.-M., A.S., and A.L.; methodology, J.M.G.-M., A.S., I.R.-G., I.A., and A.M.H.-O.; formal analysis, A.S., I.R.-G., I.A., and A.M.H.-O.; data curation, I.R.-G., I.A., and A.M.H.-O.; writing—original draft preparation, A.M.H.-O.; writing—review and editing, A.S., I.A., and A.L.; visualization, A.S. and A.L.; supervision, A.S. and A.L. All authors have read and agreed to the published version of the manuscript.

Funding: This Research by A.L. is funded by the Spanish Ministry of Science and Innovation (Fondo de Investigaciones Sanitarias) and Fonds Feder, grant number PI18/00139. Irene Rodriguez Gomez received a postdoctoral contract from the Government of Castilla-La Mancha (2019/13). Kullberg, S.; Rivera, N.; Eriksson, M.J.; Grunewald, J.; Eklund, A. High-intensity resistance training in newly diagnosed sarcoidosis- an exploratory study of effects on lung function, muscle strength, fatigue, dyspnea, health-related quality of life and lung immune cells. Eur. Clin. Respir. J. 2020, 7, 1730137. [CrossRef] [PubMed]

Conflicts of Interest: The authors declare no conflict of interests.

References
1. Arkema, E.V.; Cozier, Y.C. Epidemiology of sarcoidosis: Current findings and future directions. Ther. Adv. Chronic Dis. 2018, 9, 227–240. [CrossRef] [PubMed]
2. Tavana, S.; Alizadeh, M.; Mohajerani, S.; Hashemian, S. Pulmonary and extra-pulmonary manifestations of sarcoidosis. Niger. Med. J. 2015, 56, 258. [CrossRef] [PubMed]
3. Voortman, M.; Hendriks, C.M.R.; Elfferich, M.D.P.; Bonella, F.; Moller, J.; de Vries, J.; Costabel, U.; Drent, M. The burden of sarcoidosis symptoms from a patient perspective. Lung 2019, 197, 155–161. [CrossRef] [PubMed]
4. Judson, M.A. The clinical features of sarcoidosis: A comprehensive review. Clin. Rev. Allergy Immunol. 2015, 49, 63–78. [CrossRef] [PubMed]
5. Boucly, A.; Cottin, V.; Nunes, H.; Jaïs, X.; Tazi, A.; Prévôt, G.; Reynaud-Gaubert, M.; Dromer, C.; Viacroze, C.; Horeau-Langlard, D.; et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur. Respir. J. 2017, 50. [CrossRef]
6. Moor, C.C.; Gür-Demirel, Y.; Wijsenbeek, M.S. Feasibility of a comprehensive home monitoring program for sarcoidosis. J. Personal. Med. 2019, 2, e109. [CrossRef]
7. Cho, P.S.P.; Vasudevan, S.; Maddocks, M.; Spinou, A.; Mitchell, S.C.; Wood, C.; Jolley, C.J.; Birring, S.S. Physical inactivity in pulmonary sarcoidosis. Lung 2019, 197, 285–293. [CrossRef]
8. Froidure, S.; Kyheng, M.; Grosbois, J.M.; Lhuissier, F.; Stelianides, S.; Wemeau, L.; Wallaert, B. Daily life physical activity in patients with chronic stage IV sarcoidosis: A multicenter cohort study. Health Sci. Rep. 2019, 2, e109. [CrossRef]
9. Bahmer, T.; Watz, H.; Develaska, M.; Waschki, B.; Rabe, K.F.; Magnusson, H.; Kirsten, D.; Kirsten, A.-M. Physical activity and fatigue in patients with sarcoidosis. Respiration 2018, 95, 18–26. [CrossRef]
10. Strookapp, B.; Saketkoo, L.A.; Elfferich, M.; Holland, A.; de Vries, J.; Knevel, T.; Drent, M. Physical activity and training in sarcoidosis: Review and experience-based recommendations. Expert Rev. Respir. Med. 2016, 10, 1057–1068. [CrossRef]
11. Strookapp, B.; Elfferich, M.; Swigris, J.; Verschoof, A.; Vesak, G.; Knevel, T.; Drent, M. Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: A pilot study. Sarcoidosis Vasc. Diffuse Lung Dis. 2015, 32, 43–52. [PubMed]
12. Marcellis, R.; van der Veeke, M.; Mesters, I.; Drent, M.; de Bie, R.; de Vries, G.; Lenssen, A. Does physical training reduce fatigue in sarcoidosis? Sarcoidosis Vasc. Diffuse Lung Dis. 2015, 32, 53–62. [PubMed]
13. Küllberg, S.; Rivera, N.; Eriksson, M.J.; Grunewald, J.; Eklund, A. High-intensity resistance training in newly diagnosed sarcoidosis- an exploratory study of effects on lung function, muscle strength, fatigue, dyspnea, health-related quality of life and lung immune cells. Eur. Clin. Respir. J. 2020, 7, 1730137. [CrossRef] [PubMed]
14. Strookapp, B.; Swigris, J.; de Vries, J.; Elfferich, M.; Knevel, T.; Drent, M. Benefits of physical training in sarcoidosis. Lung 2015, 193, 701–708. [CrossRef] [PubMed]
15. Naz, I.; Ozalevli, S.; Ozkan, S.; Sahin, H. Efficacy of a structured exercise program for improving functional capacity and quality of life in patients with stage 3 and 4 sarcoidosis: A randomized controlled trial. J. Cardiopulm. Rehabil. Prev. 2018, 38, 124–130. [CrossRef] [PubMed]
16. Gibala, M.J.; Little, J.P.; Macdonald, M.J.; Hawley, J.A. Physiological adaptations to low-volumne, high-intensity interval training in health and disease. *J. Physiol.* 2012, 590, 1077–1084. [CrossRef] [PubMed]

17. Grongstad, A.; Vollestad, N.; Oldervoll, L.; Spruit, M.; Edvardsen, A. The effects of high- versus moderate-intensity exercise on fatigue in sarcoidosis. *J. Clin. Med.* 2019, 8, 460. [CrossRef]

18. Gangemi, A.; Myers, C.N.; Zheng, M.; Brown, J.; Butler-Lebair, M.; Cordova, F.; Marchetti, N.; Criner, G.J.; Gupta, R.; Mamary, A.J. Mortality for sarcoidosis patients on the transplant wait list in the Lung Allocation Score era: Experience from a high volume center. *Respir. Med.* 2019, 157, 69–76. [CrossRef]

19. Marcellis, R.G.J.; Lenssen, A.F.; de Vries, J.; Drent, M. Reduced muscle strength, exercise intolerance and disabling symptoms in sarcoidosis. *Curr. Opin. Pulm. Med.* 2013, 19, 524–530. [CrossRef]

20. Brancaleone, P.; Perez, T.; Robin, S.; Neviere, R.; Wallaert, B. Clinical impact of inspiratory muscle impairment in sarcoidosis. *Sarcoidosis Vasc. Diffuse Lung Dis.* 2004, 21, 219–227.

21. Hunninghake, G.W.; Costabel, U.; Ando, M.; Baughman, R.; Cordier, J.F.; Bois, R.; Eklund, A.; Kitaichi, M.; Lynch, J.; Rizzato, G.; et al. Statement on sarcoidosis. *Am. J. Respir. Crit. Care Med.* 1999, 160, 736–755. [CrossRef]

22. González-Saiz, L.; Fiuza-Luces, C.; Sanchis-Gomar, F.; Santos-Lozano, A.; Quezada-Loaiza, C.A.; Flox-Camacho, A.; Munguia-Izquierdo, D.; Ara, I.; Santalla, A.; Morán, M.; et al. Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: The WHOLEi + 12 trial. *Int. J. Cardiol.* 2017, 231, 277–283. [CrossRef] [PubMed]

23. Zach, M.S. The physiology of forced expiration. *Paediatr. Respir. Rev.* 2000, 1, 36–39. [CrossRef] [PubMed]

24. Lopes, A.J.; Menezes, S.L.S.; Dias, C.M.; Oliveira, J.F.; Mainenti, M.R.M.; Guimarães, F.S. Cardiopulmonary exercise testing variables as predictors of long-term outcome in thoracic sarcoidosis. *Brz. J. Med. Biol. Res.* 2012, 45, 256–263. [CrossRef]

25. Lucia, A.; Hoyos, J.; Chicharro, J.L. Preferred pedalling frequency in professional cycling. *Med. Sci. Sports Exerc.* 2001, 33, 1361–1366. [CrossRef]

26. Rodríguez-Gómez, I.; Santalla, A.; Dietz-Bermejo, J.; Munguia-Izquierdo, D.; Alegre, L.M.; Nogales-Gadea, G.; Arenas, J.; Martín, M.A.; Lucia, A.; Ara, I. A new condition in McArdle disease: Poor bone HealthBenefits of an active lifestyle. *Med. Sci. Sports Exerc.* 2018, 50, 3–10. [CrossRef] [PubMed]

27. Bailey, C.A.; Brooke-Wavell, K. Optimum frequency of exercise for bone health: Randomised controlled trial of a high-impact unilateral intervention. *Bone* 2010, 46, 1043–1049. [CrossRef]

28. Kemmler, W.; Kohl, M.; von Stengel, S. Long-term e

29. Layton, A.M.; Armstrong, H.F.; Baldwin, M.R.; Podolanczuk, A.J.; Pieszchata, N.M.; Singer, J.P.; Arcasoy, S.M.; Meza, K.S.; D’Ovidio, F.; Lederer, D.J. Frailty and maximal exercise capacity in adult lung transplant candidates. *Respir. Med.* 2017, 131, 70–76. [CrossRef] [PubMed]
36. MacInnis, M.J.; Gibala, M.J. Physiological adaptations to interval training and the role of exercise intensity. *J. Physiol.* 2017, 595, 2915–2930. [CrossRef]  
37. Bloor, C.M. Angiogenesis during exercise and training. *Angiogenesis* 2005, 8, 263–271. [CrossRef] [PubMed]  
38. Habedank, D.; Reindl, I.; Vitzke, G.; Bauer, U.; Sperfeld, A.; Wernecke, K.D.; Kleber, F.X. Ventilatory efficiency and exercise tolerance in 101 healthy volunteers. *Eur. J. Appl. Physiol. Occup. Physiol.* 1998, 77, 421–426. [CrossRef]  
39. Karadall, M.N.; Bošnak-Güçlü, M.; Camçoğlu, B.; Kokturk, N.; Tükta, H. Effects of inspiratory muscle training in subjects with sarcoidosis: A randomized controlled clinical trial. *Respir. Care* 2016, 61, 483–494. [CrossRef]  
40. Souza, H.; Rocha, T.; Pessoa, M.; Rattes, C.; Brandão, D.; Fregonezi, G.; Campos, S.; Aliverti, A.; Dornelas, A. Effects of inspiratory muscle training in elderly women on respiratory muscle strength, diaphragm thickness and mobility. *J. Gerontol. A Biol. Sci. Med. Sci.* 2014, 69, 1545–1553. [CrossRef]  
41. Shei, R.J.; Paris, H.L.R.; Wilhite, D.P.; Chapman, R.F.; Mickleborough, T.D. The role of inspiratory muscle training in the management of asthma and exercise-induced bronchoconstriction. *Phys. Sportsmed.* 2016, 44, 327–334. [CrossRef] [PubMed]  
42. Dempsey, J.A.; Romer, L.; Rodman, J.; Miller, J.; Smith, C. Consequences of exercise-induced respiratory muscle work. *Respir. Physiol. Neurobiol.* 2006, 151, 242–250. [CrossRef] [PubMed]  
43. Hoff, J.; Gran, A.; Helgerud, J. Maximal strength training improves aerobic endurance performance. *Scand. J. Med. Sci. Sports* 2002, 12, 288–295. [CrossRef] [PubMed]  
44. Heggelund, J.; Fimland, M.S.; Helgerud, J.; Hoff, J. Maximal strength training improves work economy, rate of force development and maximal strength more than conventional strength training. *Eur. J. Appl. Physiol.* 2013, 113, 1565–1573. [CrossRef] [PubMed]  
45. Ono, Y.; Miyakoshi, N.; Kasukawa, Y.; Akagawa, M.; Kimura, R.; Nagahata, I.; Yuasa, Y.; Sato, C.; Shimada, Y. Diagnosis of presarcopenia using body height and arm span for postmenopausal osteoporosis. *Clin. Interv. Aging.* 2020, 15, 357–361. [CrossRef] [PubMed]  
46. Stanbury, R.M.; Graham, E.M. Systemic corticosteroid therapy side effects and their management. *Br. J. Ophthalmol.* 1998, 82, 704–708. [CrossRef]  
47. Owczarek, J.; Jasińska, M.; Orszulak-Michalak, D. Drug-induced myopathies. An overview of the possible mechanisms. *Pharmacol. Rep.* 2005, 57, 23–34. [CrossRef]  
48. Kamen, G. Aging, resistance training, and motor unit discharge behavior. *Can. J. Appl. Physiol.* 2005, 30, 341–351. [CrossRef]  
49. Jenkins, N.D.; Miramonti, A.A.; Hill, E.C.; Smith, C.M.; Cochrane-Snyman, K.C.; Housh, T.J.; Cramer, J.T. Greater neural adaptations following high- vs. low-load resistance training. *Front. Physiol.* 2017, 8, 331. [CrossRef]  
50. Sipilä, S.; Törmäkangas, T.; Sillanpää, E.; Aukee, P.; Kujala, U.M.; Kovanen, V.; Laakkonen, E.K. Muscle and bone mass in middle-aged women: Role of menopausal status and physical activity. *J. Cachexia Sarcopenia Muscle.* 2020, 11, 698–709. [CrossRef]  
51. García-Bustinduy, M.; Gantes, M.A. Corticoides y osteoporosis. *Actas Dermo Sifiliogr.* 2007, 98, 526–530. [CrossRef]  
52. Greendale, G.A.; Sternfeld, B.; Huang, M.; Han, W.; Karvonen-Gutierrez, C.; Ruppert, K.; Cauley, J.A.; Finkelstein, J.S.; Jiang, S.-F.; Karlama, A.S. Changes in body composition and weight during the menopause transition. *JCI Insight.* 2019, 4, e124865. [CrossRef] [PubMed]  

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.